US Political Figures and Psychedelic Drug Research
President Trump has signed an executive order to accelerate research and ease restrictions on psychedelic drug treatments for mental health disorders. This move has drawn attention from various political figures and media outlets, including podcaster Joe Rogan.
Latest Developments
The Federal Move That Sent Psychedelics Stocks Flying - Investor's Business Daily
A federal move caused a significant surge in the stock prices of companies in the psychedelics sector. This action by the U.S. government directly impacted investor confidence and market valuation for businesses focused on psychedelic compounds. The immediate consequence was a notable increase in the value of psychedelics stocks, as reported by Investor's Business Daily. This suggests a perceived shift in regulatory or policy outlook that investors believe will benefit the industry.
Trump announces reforms to accelerate access to psychedelic drug treatments - The Guardian
President Donald Trump announced reforms aimed at accelerating access to psychedelic drug treatments, as reported by The Guardian. This initiative focuses on streamlining regulatory processes to make these therapies more readily available to patients. The move signals a shift in the Trump administration's approach to mental health and substance abuse treatment, potentially broadening the scope of approved medical interventions. This could lead to increased research and development in psychedelic medicine, offering new options for conditions like PTSD and depression.
Podcasters, Presidents, and Psychedelics: How Joe Rogan Got Trump Into Ibogaine
President Trump signed an executive order on Saturday to accelerate research on certain psychedelic drugs for conditions like depression. Podcaster Joe Rogan stood with him and was cited by Trump as a major inspiration for fast-tracking ibogaine, which Rogan has championed for years. The order aims to ease access to ibogaine, used outside the U.S. for post-traumatic stress disorder. Billionaire tech investor Peter Thiel has invested heavily in psychedelic pharmaceutical companies like Compass Pathways and AtaiBeckley, whose stocks spiked on news of Trump's likely approval. The state of Texas also announced $50 million for ibogaine clinical trials in late March.
Trump signs executive order accelerating research into psychedelic drug therapies
President Donald Trump signed an executive order Saturday to accelerate research and approval of psychedelic-based therapies. This order specifically targets conditions like PTSD, aiming to streamline the development of these treatments. The move signals the Trump administration's intent to explore alternative medical approaches for mental health and trauma. This initiative could potentially broaden access to novel treatments for veterans and others suffering from these conditions.
Trump signs order fast tracking review of psychedelics for mental health disorders - NPR
President Donald Trump signed an order to fast-track the review of psychedelics for mental health disorders, as reported by NPR. This executive action aims to accelerate the process by which certain psychedelic substances, like psilocybin or MDMA, could be approved for therapeutic use. The move reflects a growing interest in exploring alternative treatments for conditions such as PTSD, depression, and anxiety, which have shown promising results in preliminary studies. By expediting the review, the Trump administration is signaling a shift in federal policy regarding these previously restricted substances. This could potentially lead to quicker access to new treatment options for millions of Americans suffering from mental health challenges.
Key Facts
President Trump signed an executive order to accelerate research into psychedelic drug treatments for mental health disorders.
Source: The Guardian, ABC News
The order aims to fast-track the review process for psychedelics like psilocybin and ibogaine.
Source: NPR, CBS News
Podcaster Joe Rogan was present with President Trump during the signing of the executive order.
Source: Al Jazeera, Mother Jones
Trump reportedly inquired about receiving psychedelic treatments himself.
Source: CNN
Recent Highlights
Podcaster Joe Rogan joins President Trump during the signing event, highlighting his influence on the issue.
President Trump signs an executive order to accelerate research and ease restrictions on psychedelic drug treatments.
News outlets report on the details of the executive order and Trump's personal interest in the treatments.
Full Coverage (12 articles)
The Federal Move That Sent Psychedelics Stocks Flying - Investor's Business Daily
A federal move caused a significant surge in the stock prices of companies in the psychedelics sector. This action by the U.S. government directly impacted investor confidence and market valuation for businesses focused on psychedelic compounds. The immediate consequence was a notable increase in the value of psychedelics stocks, as reported by Investor's Business Daily. This suggests a perceived shift in regulatory or policy outlook that investors believe will benefit the industry.
Trump announces reforms to accelerate access to psychedelic drug treatments - The Guardian
President Donald Trump announced reforms aimed at accelerating access to psychedelic drug treatments, as reported by The Guardian. This initiative focuses on streamlining regulatory processes to make these therapies more readily available to patients. The move signals a shift in the Trump administration's approach to mental health and substance abuse treatment, potentially broadening the scope of approved medical interventions. This could lead to increased research and development in psychedelic medicine, offering new options for conditions like PTSD and depression.
Podcasters, Presidents, and Psychedelics: How Joe Rogan Got Trump Into Ibogaine
President Trump signed an executive order on Saturday to accelerate research on certain psychedelic drugs for conditions like depression. Podcaster Joe Rogan stood with him and was cited by Trump as a major inspiration for fast-tracking ibogaine, which Rogan has championed for years. The order aims to ease access to ibogaine, used outside the U.S. for post-traumatic stress disorder. Billionaire tech investor Peter Thiel has invested heavily in psychedelic pharmaceutical companies like Compass Pathways and AtaiBeckley, whose stocks spiked on news of Trump's likely approval. The state of Texas also announced $50 million for ibogaine clinical trials in late March.
Trump signs executive order accelerating research into psychedelic drug therapies
President Donald Trump signed an executive order Saturday to accelerate research and approval of psychedelic-based therapies. This order specifically targets conditions like PTSD, aiming to streamline the development of these treatments. The move signals the Trump administration's intent to explore alternative medical approaches for mental health and trauma. This initiative could potentially broaden access to novel treatments for veterans and others suffering from these conditions.
Trump signs order fast tracking review of psychedelics for mental health disorders
President Donald Trump signed an order to fast-track the review of psychedelics for mental health disorders. The President endorsed psilocybin and ibogaine as part of this initiative. This action aims to accelerate the evaluation process for these substances. The order reflects a White House focus on potential alternative treatments for mental health.
Trump signs order fast tracking review of psychedelics for mental health disorders - NPR
President Donald Trump signed an order to fast-track the review of psychedelics for mental health disorders, as reported by NPR. This executive action aims to accelerate the process by which certain psychedelic substances, like psilocybin or MDMA, could be approved for therapeutic use. The move reflects a growing interest in exploring alternative treatments for conditions such as PTSD, depression, and anxiety, which have shown promising results in preliminary studies. By expediting the review, the Trump administration is signaling a shift in federal policy regarding these previously restricted substances. This could potentially lead to quicker access to new treatment options for millions of Americans suffering from mental health challenges.
Trump Signs Executive Order to Loosen Restrictions on Psychedelic Drugs - The New York Times
President Trump signed an Executive Order aimed at loosening restrictions on psychedelic drugs, as reported by The New York Times. This action reflects a growing interest in the potential therapeutic applications of substances like psilocybin and MDMA for conditions such as PTSD and depression. The Executive Order could streamline research and potentially accelerate the development of new treatments involving these compounds. This move by the Trump administration signals a shift in federal policy regarding these previously highly controlled substances.
Trump joined by Joe Rogan as he signs order to speed up psychedelic review
President Trump, joined by Joe Rogan, signed an order aimed at accelerating the federal review process for psychedelics. The executive order specifically directs the federal government to relax restrictions on psychedelics, including ibogaine, for their potential use as treatments. This action signals a significant shift in federal policy regarding these substances, potentially easing their path toward medical applications. The move could facilitate research and development into psychedelic-assisted therapies for various conditions.
Watch: Trump signs executive order easing U.S. restrictions on psychedelic research
President Trump signed an executive order on Saturday to ease restrictions on research into psychedelics. This order specifically mentions the drug ibogaine, which is used in some countries to treat post-traumatic stress disorder. The move signals a potential shift in the federal government's approach to studying these substances for therapeutic applications. This action could facilitate new scientific investigations into psychedelics as treatments for various conditions.
Trump signs order to hasten review of psychedelics
President Trump signed an order to expedite the review process for psychedelics, aiming to accelerate research into their potential medical applications. This action comes despite psychedelics like Ibogaine remaining in the federal government's most restrictive category for illegal, high-risk drugs. The Trump administration is seeking to ease current restrictions to spur studies on using these substances for conditions such as severe depression. This initiative could lead to significant changes in how psychedelics are researched and potentially utilized for therapeutic purposes in the United States.
Trump accelerates research on psychedelic treatments and asks, ‘Can I have some?’ - CNN
President Donald Trump is accelerating research into psychedelic treatments and personally inquired about receiving them, according to CNN. This initiative marks a significant shift in federal policy regarding substances like psilocybin and MDMA, which have historically been subject to strict federal prohibitions. The move suggests a potential expansion of federally funded studies into psychedelics for therapeutic uses, particularly for conditions like PTSD and depression. Such an acceleration could lead to new treatment options for veterans and others suffering from mental health challenges. President Trump's personal interest highlights a growing bipartisan curiosity in the medical potential of these compounds.
Trump announces reforms to accelerate access to psychedelic drug treatments
President Donald Trump signed an executive order on Saturday to accelerate access to psychedelic drug treatments. The order specifically directs the federal Food and Drug Administration (FDA) to expedite its review process for psychedelic drugs, including ibogaine. This action aims to speed up medical research and treatment options for conditions like post-traumatic stress disorder (PTSD). US military veteran groups have advocated for ibogaine, citing its potential to treat PTSD. The Trump administration's move could significantly alter the regulatory landscape for these substances.